Axumin PET scan

PreclinicalSmall molecule

UUniversity of Texas Southwestern Medical Center

Axumin PET scan is one of 17 small molecule programs targeting Germ Cell Tumor. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Germ Cell TumorActive, not recruiting

Germ Cell TumorPreclinical

Active, not recruiting

Competition

Competitive Landscape

18 competitors in Germ Cell Tumor

#DrugCompanyPhaseTrials

Antabuse

Gemzar

Iressa

Afinitor

Ellence

Taxol

14 7

Blenoxane

Bristol-Myers Squibb

Phase 3

10 8

Vepesid

AAvyxa

Phase 3

23 9

Paraplatin

AAvyxa

Phase 3

22 10

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Germ Cell Tumor1 trial

Role of Axumin PET Scan in Germ Cell Tumor

Completed·UUniversity of Texas Southwestern Medical Center··NCT03426865·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Axumin PET scan. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Axumin PET scan compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Axumin PET scan. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Texas Southwestern Medical Center company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity of Texas Southwestern Medical Center

Axumin PET scan

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Germ Cell Tumor1 trial

References

Drug Info

Quick Facts

Related News